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BACKGROUND: Recently, oncogenic G protein alpha subunit q (GNAQ) mutations have been described in about 50% of uveal
melanomas and in the blue nevi of the skin.
METHODS: GNAQ exon 5 was amplified from 75 ciliary body and choroidal melanoma DNAs and sequenced directly. GNAQ mutation
status was correlated with disease-free survival (DFS), as well as other clinical and histopathological factors, and with chromosomal
variations detected by FISH and CGH.
RESULTS: Of the 75 tumour DNA samples analysed, 40 (53.3%) harboured oncogenic mutations in GNAQ codon 209. Univariate and
multivariate analysis showed that GNAQ mutation status was not significantly correlated with DFS.
CONCLUSION: The GNAQ mutation status is not suitable to predict DFS. However, the high frequency of GNAQ mutations may render
it a promising target for therapeutic intervention.
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Cutaneous melanocytic nevi and melanomas show frequent
oncogenic mutations in BRAF and NRAS, and consequent
constitutive activation of the MAP-kinase pathway (Davies et al,
2002; Pollock et al, 2003). In contrast, melanocytic tumours such as
uveal melanomas rarely show BRAF and NRAS mutations (Kilic
et al, 2004; Saldanha et al, 2004; Janssen et al, 2008; Maat et al,
2008). Recently, somatic mutations in the heterotrimeric G protein
alpha subunit q (GNAQ) have been found to be associated with
dominant dark skin in a large-scale mutagenesis screen of inbred
C3HeB/FeJ mice (Van Raamsdonk et al, 2004). In humans, GNAQ
was found to be frequently mutated in the blue nevi of the skin
(83%) and uveal melanoma (46%) (Van Raamsdonk et al, 2009).
The mutations occur exclusively in codon 209 in the ras-like
domain and result in constitutive activation, turning GNAQ into a
dominant acting oncogene, activating the MAP-kinase pathway.
We asked whether oncogenic GNAQ mutations in uveal melanoma
are associated with patient survival.
MATERIALS AND METHODS
Patients and tumour material
Ciliary body or choroidal melanomas were collected from patients
who underwent enucleation of the tumour-containing eye at the
Erasmus MC Rotterdam or Rotterdam Eye Hospital (Rotterdam,
The Netherlands). Informed consent was obtained before enuclea-
tion and the study was performed according to the tenets of the
Declaration of Helsinki. Fresh tumour material was obtained
within 1h after enucleation and processed for FISH and
cytogenetic analysis as described (Kilic et al, 2005). A fraction of
each tumour was snap-frozen and stored in liquid nitrogen. The
remainder of the eye was embedded in paraffin and sections were
stained with haematoxylin and eosin (H&E) for evaluation. All
tumours were confirmed histopathologically as uveal melanomas
(on the basis of H&E morphology, mitotic activity, and results of
HMB45 and S100 staining). Seventy-five patients were selected
from our extensive database with information on follow-up and
clinical, cytogenetic and histopathological parameters.
FISH and CGH analysis
Dual-colour FISH on uncultured tumour material using centro-
meric and locus-specific cosmid, P1 or YAC probes for chromo-
some 1, 3, 6 and 8 was performed as described previously (Kilic
et al, 2005). CGH analysis was performed on DNA from formalin-
fixed paraffin-embedded tumour material as described previously
(Kilic et al, 2005).
GNAQ mutation analysis
GNAQ exon 5, which includes the mutational hotspot codon 209,
was amplified from uveal melanoma biopsy DNA using PCR and the
primers 50-CCCACACCCTACTTTCTATCATTTAC-30 and 50-TT
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sTTCCCTAAGTTTGTAAGTAGTGC-30. PCR products were purified
using ExoSAP-IT (USB, Staufen, Germany), and sequenced in reverse
direction directly on an ABI Prism 3700 DNA Analyzer (Applied
Biosystems, Foster City, CA, USA).
Statistical analysis
The primary end point for disease-free survival (DFS) was the time
to development of metastatic disease; death due to other causes
was treated as censored. Statistical analyses were performed with
SPSS software, release 16.0 (Munich, Germany). Actuarial prob-
abilities of DFS (with an event defined as development of
metastatic disease or death by disease) were estimated according
to the Kaplan–Meier method. To examine the possibility that
other clinical, histopathological or chromosomal variations
affected the prognosis, we performed Cox proportional hazard
analysis for each confounding variable. An effect was considered
significant if the P-value was p0.05.
RESULTS
Tumour pathology and clinical outcome
A total of 75 uveal melanomas were included in the study. The
median age of the patients at the time of enucleation was 62 years
(range 21–86). In all, 39 patients were female and 36 male. Based
on their cell type 14 tumours were classified as epithelioid, 28 as
mixed, and 33 as spindle cell type. The mean tumour diameter and
thickness were 13.4mm (range 7.0–19.0) and 8.4mm (range 1.5–
20.0), respectively. At the end of the follow-up (mean 56.1 and
range 6.4–136.4 months), 28 patients died of melanoma-related
disease, 1 patient was diagnosed with metastases, 9 patients died
due to other causes and 37 patients were still alive without
metastases.
Molecular genetic analysis
All uveal melanomas were analysed for the oncogenic GNAQ
mutation and chromosomal changes of chromosomes 3 and 8. Of
the 75 tumour DNA samples analysed, 40 (53.3%) harboured
oncogenic mutations in GNAQ codon 209. In detail, 29 cases
showed a heterozygous Q209P mutation, 1 case a homozygous
Q209P mutation, 9 cases a heterozygous Q209L and 1 case a Q209R
mutation. The copy number of chromosome 3 was obtained in 74
uveal melanomas, and of chromosomal region 8q in 68 uveal
melanomas.
Statistical analysis
Univariate analysis was performed for all parameters, showing a
lower DFS for patients with loss of chromosome 3 and gain of
chromosome 8q. Univariate analysis of GNAQ mutated cases
compared with wild-type tumours did not show a significantly
decreased DFS (P¼0.273) (Figure 1). To examine the possibility
that GNAQ mutations may affect the prognosis of patients with
loss of one copy of chromosome 3, we calculated Kaplan–Meier
survival curves of GNAQ status stratified for chromosome 3 status
and performed log rank tests (P¼0.559) (Figure 2). Disease-free
survival was not modified by the presence of GNAQ mutations. In
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Figure 1 Kaplan–Meier survival curve of tumours harbouring mutated vs
wild-type GNAQ. The black line represents mutated, and the grey line
represents wild type. The table shows the number of events and cases at
risk over time at the respective time points.
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Figure 2 Kaplan–Meier survival curve of GNAQ mutations vs wild type stratified for loss of chromosome 3. Black line represents mutated GNAQ, and the
grey line represents wild type. The table shows the number of events and cases at risk over time at the respective time points.
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stumours with two copies of chromosome 3 the patients with a
GNAQ mutation seemed to have a better prognosis, although it was
not significant (P¼0.097). Correlations between the clinical,
chromosomal parameters and GNAQ mutation were calculated
using Mann–Whitney and Fisher’s exact tests (Table 1). We did
not observe any significant correlations. When analysed in a
multivariate model with GNAQ as a confounding variable, we
obtained a hazard ratio of 1.07 with a P-value of 0.854 (data
not shown).
DISCUSSION
In a cohort of 75 uveal melanoma patients, we could show that DFS
was not significantly correlated with GNAQ mutation status.
However, analysis stratified for loss of chromosome 3 as well as
multivariate analysis was clearly limited by the small sample size,
and hence the results should be interpreted with caution.
The mutation frequency of GNAQ codon 209 (53%) was in the
same range as that in a recent report by Onken et al (2008) (49%)
and by Van Raamsdonk et al (2004) (46%), confirming the
importance of oncogenic GNAQ mutations in uveal melanoma.
However, GNAQ mutations have been shown to have similar
frequencies at all clinical stages of uveal melanoma progression,
and to be independent of chromosomal aberrations, hinting at
GNAQ being an early or initiating oncogenic event (Onken et al,
2008). This is consistent with the assumption that frequent
oncogenic mutations of BRAF and NRAS in cutaneous melanoma
as well as in benign melanocytic nevi (Davies et al, 2002; Pollock
et al, 2003), which also activate the MAP-kinase pathway, are early
events and are not associated with clinical outcome (Shinozaki
et al, 2004; Akslen et al, 2005; Edlundh-Rose et al, 2006).
In conclusion, we could show that oncogenic GNAQ mutations
are not suitable to predict the clinical outcome in uveal melanoma.
However, the high frequency of GNAQ mutations may render it a
promising target for therapeutic intervention.
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Table 1 Correlation between GNAQ mutation and chromosomal
abnormalities and clinical data
GNAQ mutation status
Mutated Wild type P-value
Clinical data
Gender
Male 17 19 0.555
Female 18 21
Mean age (years) 64.5 60.5 0.220
Cell type
Spindle 15 18 0.519
Mixed/epithelioid 20 22
Mean tumour diameter 12.9 13.8 0.205
Mean tumour thickness 8.3 8.5 0.842
Involvement of the ciliary body
Yes 6 5 0.404
No 29 35
Chromosomal abnormalities
Chromosome 3 loss
Yes 22 18 0.094
No 13 22
Chromosome 8q gain
Yes 22 21 0.100
No 8 17
GNAQ¼G protein alpha subunit q.
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